Table 3.
Univariate and stepwise multivariate analyses of factors associated with overall survival.
| Comparison | Univariate analyses | Stepwise multivariate analyses | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age (years) | ≥60 vs. <60 | 0.785 (0.483–1.276) | 0.328 | ||
| Gender | Male vs. Female | 1.132 (0.694–1.849) | 0.619 | ||
| BMI(kg/m2) | ≥25 vs. <25 | 0.683 (0.410–1.135) | 0.141 | ||
| DM | Yes vs. No | 1.365 (0.785–2.374) | 0.270 | ||
| Sarcopenia | Yes vs. No | 1.226 (0.725–2.073) | 0.447 | ||
| Synchronous | Yes vs. No | 0.911 (0.545–1.522) | 0.722 | ||
| Neoadjuvant chemotherapy | Yes vs. No | 1.116 (0.596–2.092) | 0.731 | ||
| Adjuvant chemotherapy | Yes vs. No | 1.303 (0.522–3.250) | 0.571 | ||
| Blood loss (cc) | ≥300 vs. <300 | 2.116 (1.293–3.461) | 0.003 | 1.793(1.084–2.964) | 0.023 |
| CEA (ng/ml) | ≥20 vs. <20 | 1.639 (1.008–2.663) | 0.046 | 1.793 (1.092–2.945) | 0.021 |
| Primary tumor site | right vs. left | 1.530 (0.775–3.021) | 0.220 | ||
| Tumor stage | T3,4 vs. 2 | 1.305 (0.622–2.735) | 0.481 | ||
| Nodal status | N2 vs. N0, 1 | 1.639 (0.981–2.739) | 0.059 | ||
| Main tumor (cm) | >3 vs. ≤3 | 1.783 (1.085–2.930) | 0.023 | ||
| Tumor number | >3 vs. ≤3 | 2.733 (1.675–4.459) | <0.001 | 2.736 (1.631–4.589) | <0.001 |
| AST (U/L) | per 1 U/L increase | 1.016 (0.999–1.032) | 0.068 | ||
| ALT (U/L) | per 1 U/L increase | 1.007 (0.992–1.022) | 0.361 | ||
| Albumin (g/dl) | per 1 g/dl increase | 0.744 (0.533–1.038) | 0.082 | ||
| Platelet (103/μL) | per 103/μL increase | 1.003 (1.001–1.005) | 0.016 | ||
| NLR | > 3 vs. ≤3 | 1.055 (0.608–1.830) | 0.849 | ||
Abbreviation: HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; CEA, carcinoembryonic antigen;
aspartate aminotransferase; ALT, alanine aminotransferase; NLR, neutrophil-to-lymphocyte ratio.